If you are interested in learning more about this study, please call or email the contact person below
|Title||A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis (NASH). 747-303|
|Description||Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment |
The study visits will be in downtown Buffalo.
|Objective||"This Phase 3, double-blind, randomized, long-term, placebo-controlled, multicenter international study will evaluate the effect of OCA on histological improvements in NASH, all-cause mortality, and liver-related clinical outcomes. Approximately 1875 subjects with biopsy-confirmed, precirrhotic NASH and evidence of liver fibrosis will be enrolled in the study, including approximately 60% with fibrosis stage 3 and no more than 40% with fibrosis stage 2. An additional cohort of 190 subjects with fibrosis stage 1 and at least |
1 accompanying comorbidity will also be enrolled for exploratory purposes, for a total of approximately 2065 subjects."
Keywords: NASH, liver fibrosis, Non-alcoholic Steatohepatitis
|Principal Investigator||TALAL, ANDREW|
|Drugs Involved|| Obeticholic Acid |
|Key Eligibility||Nonalcoholic Steatohepatitis (NASH) |
Liver fibrosis stage 1, 2 or 3
No presence of liver cirrhosis
|Disease Group||Digestive System; Liver Diseases|
|Treatment||Obeticholic Acid |
|Contact|| RICHARD REJMAN |